NDAORALTABLET, EXTENDED RELEASE
Approved
Jul 2014
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4m ago · AI intelligence enriched 4m ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TARGINIQ is a fixed-dose combination tablet containing oxycodone hydrochloride (an opioid analgesic) and naloxone hydrochloride (an opioid antagonist) in extended-release formulation. It is designed to treat moderate to severe pain while incorporating abuse-deterrent properties through naloxone, which blocks opioid effects if the tablet is tampered with or injected. The naloxone component remains inactive when the tablet is taken orally as intended.
Peak
Product is at peak lifecycle stage with moderate competitive pressure (30/100), indicating stable but challenged commercial environment where brand defense and managed care strategy are critical.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TARGINIQ offers exposure to a mature opioid franchise in a highly regulated, reimbursement-sensitive environment with significant managed care complexity. Career growth opportunities center on market defense, payer negotiation, and navigating opioid risk mitigation strategies rather than launch momentum or indication expansion.
Brand ManagerMedical Science Liaison
Worked on TARGINIQ at Purdue Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.